DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain Sells 2,090 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

DexCom Stock Performance

Shares of DXCM opened at $87.62 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market cap of $34.22 billion, a P/E ratio of 52.47, a PEG ratio of 2.23 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a 50-day moving average of $80.22 and a two-hundred day moving average of $76.59.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DXCM. Raymond James decreased their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Sanford C. Bernstein lifted their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Canaccord Genuity Group increased their price objective on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 9th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $99.29.

Institutional Investors Weigh In On DexCom

A number of institutional investors and hedge funds have recently bought and sold shares of DXCM. Creative Planning raised its holdings in shares of DexCom by 4.9% in the second quarter. Creative Planning now owns 48,693 shares of the medical device company’s stock worth $5,521,000 after acquiring an additional 2,271 shares during the last quarter. NewEdge Advisors LLC raised its stake in DexCom by 18.3% in the 2nd quarter. NewEdge Advisors LLC now owns 9,020 shares of the medical device company’s stock valued at $1,023,000 after purchasing an additional 1,393 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its holdings in DexCom by 4.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after purchasing an additional 162 shares in the last quarter. New Wave Wealth Advisors LLC purchased a new position in DexCom in the 2nd quarter valued at about $253,000. Finally, Brown Financial Advisors acquired a new stake in shares of DexCom during the 2nd quarter worth about $1,236,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.